Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

19.93 -0.04 (-0.19%)
Streaming Delayed Price Updated: 12:58 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?
When evaluating investments, it helps to keep quarterly performance in context. 
Via The Motley Fool
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. 
Via Investor's Business Daily
Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review
The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones. 
Via Investor's Business Daily
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits. 
Via Investor's Business Daily
Catalyst Pharmaceuticals: Q1 Earnings Insights
 
Via Benzinga
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is a Stock Spotlight on 4/11
Via Investor Brand Network
1 Growth Stock to Buy Before the Next Bull Market
The stock is on a roll, and the company just made a major new purchase. 
Via The Motley Fool
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales. 
Via Benzinga
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Analyst Expectations for Catalyst Pharmaceuticals's Future
 
Via Benzinga
4 Analysts Have This to Say About Catalyst Pharmaceuticals
 
Via Benzinga
Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023
The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Outlook For Catalyst Pharmaceuticals
 
Via Benzinga
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
7 A-Rated Stocks to Buy for April 2023
Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape. 
Via InvestorPlace
2 Top Growth Stocks That Can Withstand an Economic Downturn
These two drugmakers should march higher in 2023 and beyond. 
Via The Motley Fool
Why Catalyst Pharmaceuticals Shares Are Moving
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading higher by 9.66% to $15.72 Thursday morning after the company reported better-than-expected fourth-quarter results. 
Via Benzinga
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates
The guidance includes Catalyst's newest, and second, product. 
Via Investor's Business Daily
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
7 Core Stocks to Build a Solid Portfolio Around
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation. 
Via InvestorPlace
Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
2 Growth Stocks to Invest $1,000 in Right Now
Both of these biopharmas have major catalysts that are in play or drawing near. 
Via The Motley Fool
2 Breakout Growth Stocks to Buy for the Long Haul
These two stocks are entirely different, but they both make shareholders richer. 
Via The Motley Fool
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
7 Smart Stock Picks for Cautious Investors
As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors. 
Via InvestorPlace
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.